(Q46448331)

22 December 2017

title

High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia (English)

1 reference

22 December 2017

1 reference

1 reference

R F Schlenk

1

1 reference

22 December 2017

U Germing

2

1 reference

22 December 2017

F Hartmann

3

1 reference

22 December 2017

A Glasmacher

4

1 reference

22 December 2017

J T Fischer

5

1 reference

22 December 2017

F del Valle y Fuentes

6

1 reference

22 December 2017

K Götze

7

1 reference

22 December 2017

H Pralle

8

1 reference

22 December 2017

C Nerl

9

1 reference

22 December 2017

H Salwender

10

1 reference

22 December 2017

W Grimminger

11

1 reference

22 December 2017

A Petzer

12

1 reference

22 December 2017

M Hensel

13

1 reference

22 December 2017

A Benner

14

1 reference

22 December 2017

L Zick

15

1 reference

22 December 2017

K Döhner

16

1 reference

22 December 2017

S Fröhling

17

1 reference

22 December 2017

H Döhner

18

1 reference

22 December 2017

AML Study Group (AMLSG)

19

1 reference

22 December 2017

publication date

1 June 2005

1 reference

22 December 2017

published in

Leukemia

1 reference

22 December 2017

volume

19

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

978-983

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403766

exact match

0 references

cites work

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Trisomy 21 and other chromosomal abnormalities in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

7 January 2021

Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

7 January 2021

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

7 January 2021

Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

7 January 2021

Censoring distributions as a measure of follow-up in survival analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403766

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403766

1 reference

22 December 2017

1 reference

22 December 2017